Published in J Am Coll Cardiol on April 21, 2004
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol (2013) 1.70
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Evaluation of cardiac arrhythmia among athletes. Am J Med (2010) 1.45
Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol (2012) 1.44
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
Short QT syndrome. CMAJ (2005) 1.17
Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol (2005) 1.11
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09
Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol (2008) 1.07
Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance. Curr Cardiol Rev (2009) 0.98
Short QT syndrome review. J Interv Card Electrophysiol (2008) 0.90
The short QT syndrome. J Interv Card Electrophysiol (2011) 0.88
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol (2007) 0.86
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol (2016) 0.86
Congenital short QT syndrome. Indian Pacing Electrophysiol J (2010) 0.83
Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant. Br J Clin Pharmacol (2011) 0.80
Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel. PLoS One (2012) 0.78
[Primary electrical heart disease in adulthood--electrophysiological findings and therapy]. Herzschrittmacherther Elektrophysiol (2005) 0.77
Genetics of inherited primary arrhythmia disorders. Appl Clin Genet (2015) 0.77
Risk stratification in electrical cardiomyopathies. Herz (2009) 0.76
[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Genetic testing in specific cardiomyopathies. F1000 Med Rep (2009) 0.76
Long and short QT syndrome. Herzschrittmacherther Elektrophysiol (2006) 0.76
Genetic Test for the Channelopaties: Useful or Less Than Useful for Patients? (Part II). Transl Med UniSa (2013) 0.75
Your Father and Grandfather's Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia. Curr Genomics (2015) 0.75
Short QT Syndrome - Review of Diagnosis and Treatment. Arrhythm Electrophysiol Rev (2014) 0.75
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev (2016) 0.75
Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome? J Mol Cell Cardiol (2006) 0.75
Increased sensitivity to local anesthetic drugs: bedside to bench. Circ Res (2008) 0.75
Styrax blocks inward and outward current of Kir2.1 channel. Channels (Austin) (2016) 0.75
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. Card Electrophysiol Clin (2016) 0.75
Atrial fibrillation in cardiac channelopathies. Indian Pacing Electrophysiol J (2009) 0.75
Device therapy in children: current indications. Indian Pacing Electrophysiol J (2008) 0.75
Pharmacotherapy to reduce arrhythmic mortality. Indian Heart J (2014) 0.75
[Ventricular arrhythmias in ion channel diseases]. Herzschrittmacherther Elektrophysiol (2017) 0.75
PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function KIR2.1 channels, but increases channel protein expression. J Biomed Sci (2017) 0.75
Hydrocinnamic Acid Inhibits the Currents of WT and SQT3 Syndrome-Related Mutants of Kir2.1 Channel. J Membr Biol (2017) 0.75
[Short QT syndrome]. Herzschrittmacherther Elektrophysiol (2012) 0.75
The Pharmacogenomics of a Mutation 'Hotspot' for the Short QT Syndrome. JACC Clin Electrophysiol (2017) 0.75
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 4.23
Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol (2011) 4.12
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Natural history of Brugada syndrome: insights for risk stratification and management. Circulation (2002) 3.10
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77
Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol (2010) 2.75
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry. Europace (2013) 2.65
Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J (2006) 2.59
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol (2003) 2.44
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol (2005) 2.39
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Clinical aspects and prognosis of Brugada syndrome in children. Circulation (2007) 2.29
Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J (2006) 2.28
De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res (2005) 2.27
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol (2004) 2.23
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol (2009) 2.21
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation (2005) 2.20
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation (2011) 2.17
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol (2003) 2.14
Effect of opening a new catheterization laboratory on 30-day and 2-year survival rates in myocardial infarction patients. Rev Esp Cardiol (2011) 2.14
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2006) 2.11
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03